Prasinezumab: an anti-alpha-synuclein antibody in Parkinson's disease

(1:29)

PADOVA study: prasinezumab in patients with early Parkinson's disease

(2:53)

PADOVA trial: prasinezumab in early Parkinson's disease

(1:34)

Cinpanemab in Early Parkinson's Disease | NEJM

(2:5)

Could Prasinezumab be reducing motor progression in the PASADENA Open-Label Extension? -Rallying 23

(33:49)

PASADENA trial: prasinezumab in early Parkinson's disease

(1:24)

Update on the PASADENA trial of prasinezumab for Parkinson's disease

(1:57)

A post-hoc analysis of the Prasinezumab trial in early Parkinson's disease

(13:48)

PASADENA Prasinezumab 12 month data

(8:15)

Recent advances in Parkinson's disease

(1:12:16)

El Parkinson y los tratamientos: ¿Qué hay de nuevo? | Parkinson's Foundation

(1:5:45)

Markering av Den internasjonale parkinsondagen 2024

(2:32:51)

De laatste ontwikkelingen op parkinson gebied

(1:15:45)

Atypisk parkinsonisme og NAD: Du kan delta i behandlingsstudie

(21:44)

Webinar - Εκφυλιστικές και Φλεγμονώδεις Παθήσεις Εγκεφάλου

(2:16:35)

Conférence : la maladie de Parkinson

(2:19:24)

Dr. Bradley Hiner - Latest Advancements \u0026 Surgery Treatments of Parkinson's Disease

(1:1:32)

Detecting and Targeting Alpha Synuclein: Are We on a Path Toward a Cure for Parkinson's?

(38:41)

#30: Parkinson: Fortschritt in der Diagnose | Podcast Kekulés Gesundheits-Kompass | MDR

(55:23)

Exploratory delayed-start analysis of PASADENA in early-stage Parkinson's disease

(1:44)

2-Minute Neuroscience: Parkinson's Disease

(2:1econd)

How the transmission of alpha synuclein elicits Parkinson’s disease pathologies Morgan Stykel

(55:52)

Learnings from the PASADENA trial in Parkinson's disease

(1:49)

Parkinson's Disease Treatment Mode of Action Animation

(1:13)

The field of Parkinson’s disease research is expanding

(1:24)

Key clinical trials of disease modifying therapies in Parkinson's disease

(2:12)

Parkinson's Disease- Medical Research Study- May 19, 2022

(3:48)

Webinar - Clinical trials targeting alpha-synuclein

(1:5)

Stepping into the Spotlight: Challenges in the Management of PD

(17:40)